Condition
Mitral Valve (MV) Regurgitation
Total Trials
6
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Not Yet Recruiting3
Recruiting2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07069673Recruiting
Abbott Cephea Mitral Valve Disease Registry
NCT07380932Not ApplicableNot Yet Recruiting
Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair
NCT07267117Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07243197Not ApplicableNot Yet RecruitingPrimary
DragonFly M2 Pivotal Study
NCT06683729Not ApplicableNot Yet RecruitingPrimary
HighLife Clarity Treatment of Severe Mitral Regurgitation
NCT01288976CompletedPrimary
ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe
Showing all 6 trials